Chemistry:Benzydamine

From HandWiki
Short description: Locally acting nonsteroidal anti-inflammatory drug
Benzydamine
Benzydamine-2D-skeletal.png
Clinical data
Trade namesMaxtra Gargle, Difflam, Tantum
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • AU: B2
Routes of
administration
Oral, topical
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding<20%
Elimination half-life13 hours
ExcretionKidney
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC19H23N3O
Molar mass309.413 g·mol−1
3D model (JSmol)
  (verify)

Benzydamine (also known as Tantum Verde and branded in some countries as Maxtra Gargle, Difflam and Septabene), available as the hydrochloride salt, is a locally acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of inflammatory conditions of the mouth and throat.[1] It falls under class of chemicals known as indazole.

History

It was synthesized in Italy in 1964 and marketed in 1966.[2]

Uses

Medical

It may be used alone or as an adjunct to other therapy giving the possibility of increased therapeutic effect with little risk of interaction.

In some markets, the drug is supplied as an over-the-counter cream (Lonol in Mexico from Boehringer Ingelheim) used for topical treatment of musculoskeletal system disorders: sprains, strains, bursitis, tendinitis, synovitis, myalgia, periarthritis.

Recreational

Benzydamine has been used recreationally. In overdosages it acts as a deliriant and CNS stimulant.[3] Such use, particularly among teenagers, has been reported in Brazil,[4][5] Poland,[3] Romania, and Turkey.[citation needed]

Contraindications

There are no contraindications to the use of benzydamine except for known hypersensitivity.

Side effects

Benzydamine is well tolerated. Occasionally oral tissue numbness or stinging sensations may occur, as well as itching, a skin rash, skin swelling or redness, difficulty breathing and wheezing.

Pharmacology

It selectively binds to inflamed tissues (Prostaglandin synthetase inhibitor) and is normally free of adverse systemic effects. Unlike other NSAIDs, it does not inhibit cyclooxygenase or lipooxygenase, and is not ulcerogenic.[3][6] It has powerful reinforcing effect and has cross sensitization with drugs of abuse such as heroin and cocaine in animals. It is hypothesized that it has cannabinoid agonistic activity.[7]

Pharmacokinetic

Benzydamine is poorly absorbed through skin[8] and vagina.[9]

Synthesis

Benzydamine synthesis:[10][11]

Synthesis starts with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give the N-nitroso derivative. Reduction by means of sodium thiosulfate leads to the transient hydrazine (3), which undergoes spontaneous internal hydrazide formation. Treatment of the enolate of this amide with 3-chloro-1-dimethylamino propane gives benzydamine (5). Please note there is an error in this section: US3318905 states that the nitroso derivative is reduced with sodium hydrosulfite (sodium dithionite) and not with sodium hyposulfite (sodium thiosulfate), as shown in the above scheme and stated in text.

An interesting alternative synthesis of this substance starts by sequential reaction of N-benzylaniline with phosgene, and then with sodium azide to product the corresponding carbonyl azide. On heating, nitrogen is evolved and a separatable mixture of nitrene insertion product and the desired ketoindazole # results. The latter reaction appears to be a Curtius rearrangement type product to produce an N-isocyanate #, which then cyclizes. Alkylation of the enol with sodium methoxide and 3-dimethylaminopropyl chloride gives benzydamine.

Alternatively, use of chloroacetamide in the alkylation step followed by acid hydrolysis produces bendazac instead.

Research

Studies indicate that benzydamine has notable in vitro antibacterial activity and also shows synergism in combination with other antibiotics, especially tetracyclines, against antibiotic-resistant strains of Staphylococcus aureus and Pseudomonas aeruginosa.[13][14]

It also has some cannabinoid activity in rats but has not been tested in humans.[7] It is also hypothesized to act on 5-HT2A receptors due to its structural similarity with serotonin.[2]

See also

References

  1. "Benzydamine Hydrochloride (Tantum) in the management of oral inflammatory conditions". Journal 61 (2): 127–34. February 1995. PMID 7600413. 
  2. 2.0 2.1 "DEXTROMETHORPHAN AND BENZYDAMINE'S USE AND MISUSE". https://flipper.diff.org/app/items/info/6989. 
  3. 3.0 3.1 3.2 "Recreational abuse with benzydamine hydrochloride (tantum rosa)". Clinical Toxicology 45 (2): 198–9. 2007. doi:10.1080/15563650600981210. PMID 17364645. 
  4. "Recreational use of benzydamine as a hallucinogen among street youth in Brazil". Revista Brasileira de Psiquiatria 31 (3): 208–13. September 2009. doi:10.1590/S1516-44462009000300005. PMID 19784487. 
  5. "Use abusive of benzydamine in Brazil: an overview in pharmacovigilance" (in pt). Ciencia & Saude Coletiva 15 (3): 717–24. May 2010. doi:10.1590/S1413-81232010000300014. PMID 20464184. 
  6. "New pharmacologic and biochemical findings on the mechanism of action of the non-steroidal antiphlogistic, benzydamine. A synopsis" (in German). Arzneimittel-Forschung 37 (5A): 635–45. May 1987. PMID 3304305. 
  7. 7.0 7.1 "Intravenous self-administration of benzydamine, a non-steroidal anti-inflammatory drug with a central cannabinoidergic mechanism of action". Addiction Biology 23 (2): 610–619. March 2018. doi:10.1111/adb.12516. PMID 28429885. http://sro.sussex.ac.uk/id/eprint/67500/1/__smbhome.uscs.susx.ac.uk_ellenaj_Desktop_SRO_Avvisati_BZY_R2.pdf. 
  8. "Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects". Biopharmaceutics & Drug Disposition 12 (7): 481–92. October 1991. doi:10.1002/bdd.2510120702. PMID 1932611. 
  9. "Concentration of benzydamine in vaginal mucosa following local application: an experimental and clinical study". International Journal of Tissue Reactions 9 (2): 135–45. 1987. PMID 3610512. 
  10. 10.0 10.1 "Synthesis and pharmacological properties of 1-substituted 3-dimethylaminoalkoxy-1H-indazoles". Journal of Medicinal Chemistry 9 (1): 38–41. January 1966. doi:10.1021/jm00319a009. PMID 5958958. 
  11. FR patent 1382855; Palazzo, U.S. Patent 3,318,905 (1964, 1967 both to Angelini Francesco).
  12. "Ricerche nel campo degli indazoli.—Nota 1. Sulla ciclizzazione termica di azidi di acidi N-aril-N-benzil-carbamici.". Annali di Chimica 55: 116–25. 1965. 
  13. "Antimicrobial activity of benzydamine, a non-steroid anti-inflammatory agent". Journal of Chemotherapy 4 (6): 347–52. December 1992. doi:10.1080/1120009X.1992.11739190. PMID 1287137. 
  14. "Antibacterial activity of benzydamine and antibiotic-benzydamine combinations against multifold resistant clinical isolates". Arzneimittel-Forschung 46 (3): 320–3. March 1996. PMID 8901158. 

External links